Sulfonamides having antiangiogenic and anticancer activity
申请人:——
公开号:US20040157836A1
公开(公告)日:2004-08-12
Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
The present application relates to cannabinoid receptor ligands containing compounds of formula (I)
wherein A, R
1
, R
2
, and R
3
are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I:
where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof.
The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
Compounds having the formula
1
are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
[EN] IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDO-THIAZOLE EN TANT QU'INHIBITEURS DE PROTÉINES KINASES
申请人:ABBOTT LAB
公开号:WO2009070516A1
公开(公告)日:2009-06-04
Compounds of formula I that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula I and therapeutically acceptable salts, prodrugs and salts of prodrugs thereof, wherein X is CH or N; A1 is R1, OR1. NHR1, N(R1)2, NHC(O)R1, NHC(O)NHR1, NHC(O)N(R1)2, NHC(O)OR1, C(O)NHR1, C(O)N(R1)2, C=NOR1, or C(NH2)NOC(O)R1;